Silence Therapeutics plc 8-K

What Happened
Silence Therapeutics plc held its 2026 Annual General Meeting on June 16, 2026 and filed an 8-K reporting that all nine resolutions put to shareholders were duly passed on a poll. The meeting re‑appointed directors Rhonda Hellums and James Ede‑Golightly, ratified PricewaterhouseCoopers LLP as the U.S. independent registered public accounting firm and U.K. statutory auditors, and approved several corporate and governance items including the company’s 2025 U.K. Annual Report and directors’ remuneration report. The filing is signed by Iain Ross, Interim Principal Executive Officer and Chairman.

Key Details

• AGM date: June 16, 2026; Form 8‑K filed same date.
• Director votes:
  • Rhonda Hellums re‑appointed: For 47,160,731 | Against 5,557,090 | Abstain 4,680.
  • James Ede‑Golightly re‑appointed: For 52,112,045 | Against 605,683 | Abstain 4,680.
• Advisory and remuneration votes:
  • Advisory vote on named executive officer compensation (say‑on‑pay): For 48,234,208 | Against 73,667 | Abstain 4,414,536.
  • Directors’ remuneration report approved: For 48,251,875 | Against 66,518 | Abstain 4,404,018.
• Auditors and reports:
  • Ratified PwC LLP as U.S. independent registered public accounting firm: For 52,718,407 | Against 2,885 | Abstain 1,119.
  • Re‑appointed PwC as U.K. statutory auditors and authorized Audit & Risk Committee to set their remuneration.
  • Adopted 2025 U.K. Annual Report: For 52,715,076 | Against 3,108 | Abstain 4,077.
• Resolution to apply Article 159 of the company’s articles of association approved: For 48,307,317 | Against 9,333 | Abstain 4,405,761.

Why It Matters
These results confirm the company’s board composition and auditor appointments for the coming year and show shareholder approval of the company’s audited accounts and governance reports. The advisory “say‑on‑pay” and directors’ remuneration reports were approved by a clear majority, though both drew notable abstentions (over 4 million shares), a factual point investors may monitor as an indicator of shareholder engagement on pay and governance matters. Auditor ratification and adoption of the 2025 U.K. Annual Report provide continuity for financial reporting and oversight.